Kura Oncology, Inc. (NASDAQ:KURA) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET

Company Participants

Pete De Spain - Senior Vice President, Investor Relations & Corporate Communications

Troy Wilson - President & Chief Executive Officer

Tom Doyle - Senior Vice President, Finance & Accounting

Conference Call Participants

Jonathan Chang - Leerink Partners

Roger Song - Jefferies

Peter Lawson - Barclays

Li Watsek - Cantor

Bijan Mekoba - Stifel

Julian Harrison - BTIG

Reni Benjamin - JMP Securities

Operator

Good afternoon, ladies and gentlemen, and welcome to the Q2 2023 Kura Oncology, Inc. Earnings Conference Call. At this time, all lines are in listen-only mode. And following the presentation, we will conduct a question-and-answer session. [Operator Instructions]. This call is being recorded on Thursday, August 3, 2023.

I would now like to turn the conference call over to Mr. Pete De Spain, the Head of Investor Relations. Please go ahead.

Pete De Spain

Thank you, Kelsey. Good afternoon, and welcome to Kura Oncology's second quarter 2023 conference call. Joining me on the call are Dr. Troy Wilson, our President and Chief Executive Officer; and Tom Doyle, our Senior Vice President of Finance and Accounting.

Before I turn the call over to Dr. Wilson, I'd like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kura's filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company.

With that, I'll now turn the call over to Troy.

Troy Wilson

Thank you, Pete, and thank you all for joining us this afternoon. Let's jump right in. In June, we reported updated data from the KOMET-001 trial of our menin inhibitor ziftomenib, including durable activity in patients with heavily pretreated and co-mutated relapsed/refractory NPM1-mutant acute myeloid leukemia.

These data were featured during a late-breaking oral session at the European Hematology Association Annual Congress in Frankfurt. As of the April 12 data cutoff, seven of the 20 patients with NPM1-mutant AML who were treated at the recommended Phase 2 dose of 600 milligrams achieved complete remission with full count recovery for a CR rate of 35% and an overall response rate of 45%.

This represents one of the highest response rates reported for a targeted therapy in the setting of relapsed/refractory leukemia. An eighth patient who had a CR with partial count recovery after treatment with ziftomenib subsequently evolved to a CR with full count recovery after transplant and remained on study as of the date of the EHA presentation. In addition, a patient with NPM1-mutant AML treated at 200 milligrams remained on ziftomenib for 36 cycles as of the cutoff date.